The Question Behind the Paperwork
CareFirst v. Amgen is a live federal antitrust dispute about whether Amgen’s acquisition of exclusive rights to patent applications helped prolong its exclusivity over Enbrel, a biologic drug used to treat rheumatoid arthritis and other inflammatory conditions. The immediate question is not simply whether Amgen eventually owned patents, or whether a government waiting period ended. It is whether a transaction that gave a dominant firm control over flexible patent rights can be examined for its effect on competition even after later legal processes were completed. Understanding that distinction gives readers a way to read this series: follow what each legal event actually decides, then ask what remains open.
CareFirst v. Amgen asks what the transaction changed
The parties’ positions make the dispute concrete. CareFirst of Maryland and affiliated organizations sued Amgen, Immunex, and Amgen Manufacturing Limited. CareFirst alleges that Amgen acquired exclusive rights to pending applications with the potential to cover Enbrel, used those applications to obtain claims covering the drug, and then relied on the resulting patents to block lower-cost biosimilar competitors. The claim is brought under Section 2 of the Sherman Act, the provision that addresses unlawful monopolization.
The Federal Trade Commission is not a plaintiff or defendant. It filed an amicus brief in the Fourth Circuit and says it supports neither party. Its role is narrower and important: the agency is asking the appellate court to reject two categorical propositions advanced by Amgen. First, Amgen argues that acquiring a patent application can never be anticompetitive under Section 2. Second, it argues that the acquisition is protected because Amgen later prosecuted the applications before the U.S. Patent and Trademark Office and enforced the issued patents in court.
The chronology explains why those propositions matter. Roche had described etanercept, Enbrel’s active ingredient, in earlier patent applications. Immunex later obtained patents covering the drug and launched Enbrel in the United States in 1998. Immunex initially held a non-exclusive license from Roche, so Roche retained the ability to commercialize a competing version or license its rights to another potential competitor. Amgen then acquired Immunex. At that point, the key Enbrel patents were expected to expire in 2012.
In 2004, Amgen restructured the Roche arrangement. The FTC’s brief describes the new arrangement as an acquisition because Amgen obtained exclusive rights in the relevant patent family, control over prosecution of two pending Roche applications, and the ability to sue companies seeking to market etanercept biosimilars. The U.S. Patent and Trademark Office issued patents from those applications in 2011 and 2012. According to the FTC’s account, those patents covered Enbrel through April 24, 2029, and Amgen obtained permanent injunctions against Sandoz and Bioepis that lasted until that date.
That sequence does not by itself prove an antitrust violation. It does identify the factual hinge: the 2004 transaction allegedly changed who could control a still-developing patent position before the original exclusivity period ended. Looking only at the later issued patents hides that change. Looking only at the earlier license hides the shift from non-exclusive access to exclusive control. The competitive question sits in the relationship between those events.
Four legal events that are not one clearance
A useful starting point is to separate four layers that are easy to collapse into the single phrase “patent protection.” The first is the commercial acquisition: the private agreement that changes who controls an asset or a set of rights. The second is the status of the patent rights: an application may be pending, amended, continued, or eventually issued. The third is government-facing conduct: an applicant asks the USPTO to grant claims, or a patent holder asks a court to enforce them. The fourth is antitrust analysis, which asks whether the conduct acquired or maintained monopoly power through exclusionary means.
These layers can interact without becoming interchangeable. A pending application is not an issued patent. Its scope remains uncertain, and it may never issue. But the Federal Trade Commission argues that an application is not legally empty. Control over prosecution can allow claims to be amended, cancelled, or added as the applicant learns about competing products and later developments. An earlier priority date can remain attached to related claims, and continuation practice can create further opportunities to shape claims from an earlier application. The resulting uncertainty may make it harder for rivals to decide whether to invest, design around possible claims, or enter the market.
Those possibilities explain why the FTC resists a rule based only on the date of issuance. If buying a rival’s asset one day before issuance were categorically immune, while buying the same asset one day later could be scrutinized, a formal change in status would control an economically similar situation. The agency’s argument is functional: an antitrust inquiry should be able to examine what exclusive control does in the market, including the options it creates before a patent is fully matured.
The same reasoning limits the significance of a patent’s ownership. The FTC does not say that every patent acquisition violates antitrust law. It describes a narrower concern involving a monopolist, actual or potential competitors, exclusivity, and rights covering the same product or a substitute technology. Many patent transfers simply move rights without changing competitive conditions. Non-exclusive licensing and licensing that enables an inventor to commercialize an invention can be procompetitive. The question is whether this particular exclusive transaction may have impaired rivals or prolonged market power in a way unrelated to competition on the merits.
The government process matters, but for a different reason. The 2004 restructuring was submitted under the Hart-Scott-Rodino Act, and the FTC granted early termination of the waiting period. HSR is an advance-notice and waiting-period system for qualifying transactions. As the FTC’s brief explains, an agency decision that neither the FTC nor the Department of Justice intends to take action during that period is not a determination that the transaction is lawful, an endorsement of the deal, or a bar to later antitrust scrutiny. Ending the waiting period answers a timing question. It does not answer whether the completed transaction altered competition in a way that later supports a Section 2 claim.
A similar separation applies to Noerr-Pennington, the doctrine that protects legitimate efforts to influence government decision-making. Amgen’s later prosecution of the applications before the USPTO and its later enforcement litigation may receive protection as petitioning. But the FTC argues that protection for those acts does not automatically travel backward to the private acquisition that made the rights exclusively available to Amgen. A commercial transaction can have value apart from any later petition: the rights can be sold, licensed, or used to influence rivals’ decisions even if no lawsuit follows.
The layers can therefore be stated plainly. HSR waiting-period termination is not a merits clearance. Patent ownership is not a categorical antitrust exemption. A pending application is not the same as an issued patent, but neither is it necessarily irrelevant. USPTO prosecution and patent litigation may be protected petitioning, but that protection does not automatically erase an independently significant acquisition. The legal form at one layer cannot decide the competitive question at another.
What the appeal can—and cannot—settle
The district court’s reported ruling is limited but significant. After Amgen moved to dismiss, the Eastern District of Virginia rejected the argument that acquiring pending applications could never constitute anticompetitive conduct. It also concluded that although later litigation could be protected under Noerr-Pennington, the broader alleged scheme beginning with the acquisition remained actionable. The court certified both questions for interlocutory appeal under 28 U.S.C. § 1292(b). The FTC’s brief was filed in Fourth Circuit appeal No. 26-1473.
A motion-to-dismiss ruling is not a final finding that Amgen violated Section 2. It allows the legal theory and allegations to proceed. Nor does the FTC’s brief turn its position into a holding. The agency is advocating a way to keep the antitrust inquiry open; it is not deciding CareFirst’s ultimate private claim. The brief expressly distinguishes proof of an antitrust violation from the additional showing a private plaintiff must make that they suffered antitrust injury caused by the challenged conduct.
The case also does not require treating the acquisition theory as an attack on patent validity. CareFirst’s alleged injury can be framed around the acquisition and maintenance of market power, while the later patents may remain valid or invalid under separate patent-law questions. The FTC says the two inquiries should not be collapsed. A patent can be enforceable, and the commercial transaction that assembled the position can still be examined under antitrust law; whether that examination ultimately succeeds is another question.
The accessible record leaves several matters unresolved. It does not establish the relevant market definition or Amgen’s precise market share. It does not quantify damages, prove that a particular rival stayed out because of application uncertainty, or resolve the validity of the Enbrel patents. It does not provide the full HSR submission, every claim amendment, the parties’ complete appellate arguments, or a final Fourth Circuit decision. The FTC’s descriptions of the factual record and its legal conclusions must therefore remain identified as advocacy and reported allegations where appropriate.
That uncertainty does not make the dispute unimportant. It makes the distinction between legal completion and competitive scrutiny more important. A transaction can pass through an HSR waiting period, a patent application can be prosecuted, a patent can issue, and a later lawsuit can be protected petitioning. None of those facts, standing alone, answers whether the earlier acquisition changed the competitive structure. To understand why, the next question is the one the later patent obscures: what control of a pending application makes possible before it becomes a patent?